Port of Spain, February 9, 2024: The Ministry of Health (MoH), via its Chemistry, Food and Drugs Division, advises of a voluntary recall notice of Zenzedi CII (dextroamphetamine sulfate tablets, USP) 30 mg. The recall was issued by Azurity Pharmaceuticals, Inc. due to the drug Carbinoxamine Maleate, which was found in the packaging.
Zenzedi is a prescription medicine for the treatment of Narcolepsy (sleep disorder) as well as for Attention Deficit Hyperactivity Disorder (ADHD).
Patients who unknowingly consume Carbinoxamine Maleate may experience drowsiness, central nervous system depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder. For patients with ADHD and Narcolepsy, there is the possibility that accidents or injuries may occur due to the drug’s sedating effects.
The public is advised that this product is not registered for sale in the country. However, out of an abundance of caution, the Ministry advises persons who may be in possession of these recalled products to discontinue use immediately and to return the product to the place of purchase where possible.
Additional Information can be obtained by contacting the Office of the Director of the Chemistry, Food and Drug Division via email at cfdd@health.gov.tt or phone at 217-4664 ext. 13101.
The Ministry of Health will continue to monitor the situation and advise the population as necessary.
###
